Browse the full management transaction log of MultiPlan Corp, a listed issuer based in United States. Shares trade on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, MultiPlan Corp has published 82 insider filings. The latest transaction was filed on 1 July 2022 — Retenue fiscale. Among the most active insiders: Tabak Mark. Every trade is free.
25 of 82 declarations
MultiPlan Corp. was a U.S.-listed company on the NYSE under the ticker MPLN before changing its corporate name to Claritev Corporation in February 2025; for investors tracking MPLN’s history, this is the same business lineage now operating under a new market identity. The company is based in the United States, with its principal executive office in New York City at 115 Fifth Avenue, New York, NY 10003. Its operating roots go back to 1980, when MultiPlan was founded as a healthcare cost-management platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1793229/000179322922000037/a2022proxystatement14afili.htm?utm_source=openai)) Operationally, the group has been positioned as a technology and data-enabled healthcare solutions provider focused on payment integrity, network-based cost management, analytics, and decision-support tools for the U.S. healthcare system. MultiPlan stated that it served more than 700 healthcare payors, over 100,000 employers, 60 million consumers, and 1.4 million contracted providers, highlighting its broad reach across the reimbursement chain. That scale matters because the company sits in a large, recurring, and highly regulated workflow: identifying medical savings, improving payment accuracy, and helping reduce balance billing and other avoidable costs. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1793229/000179322924000136/exhibit991pressreleasedate.htm)) From a competitive standpoint, MultiPlan has long differentiated itself through a combination of proprietary data, network assets, and analytics rather than through a pure claims-processing model. In its 2016 acquisition announcement, the company described itself as the nation’s largest provider of transaction-based solutions that reduce medical costs, and as a technology-powered, data-driven cost-management business. Its client base historically included insurers, health plans, third-party administrators, self-funded employers, HMOs, and other entities that pay medical bills, which gave it a diversified end-market exposure within U.S. healthcare. ([multiplan.com](https://www.multiplan.com/webcenter/wccproxy/d?dDocName=hellman_friedman_acquisition)) Recent corporate developments have been especially important for investors. On September 20, 2024, MultiPlan completed a 1-for-40 reverse stock split, primarily intended to increase the per-share trading price to meet NYSE listing requirements. Then, on February 17, 2025, the company changed its name from MultiPlan Corporation to Claritev Corporation and announced that its common stock was expected to trade under the new ticker CTEV on the NYSE effective February 28, 2025. SEC filings also reference debt exchange and refinancing activity in late 2024 and early 2025, signaling an ongoing balance-sheet restructuring effort. For equity investors, the key takeaway is that MPLN’s operating story is a U.S.-healthcare technology and data business, but its public-market profile has been shaped materially by listing compliance actions and capital-structure adjustments. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1793229/000179322924000136/exhibit991pressreleasedate.htm?utm_source=openai))